Letter: infliximab in severe ulcerative colitis – is it useful for all patients?

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|38|11-12|1413-1413

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.38, Iss.11-12, 2013-12, pp. : 1413-1413

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Letter: infliximab in severe ulcerative colitis – is it useful for all patients? Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1413-1414

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ulcerative colitis endoscopic index of severity is associated with long‐term prognosis in ulcerative colitis patients treated with infliximab

By  

DIGESTIVE ENDOSCOPY, Vol. 28, Iss. 6, 2016-09 ,pp. : 665-670

John Wiley & Sons Inc

Access to resources Recommend Favorite

The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 10, 2015-11 ,pp. : 1192-1199

John Wiley & Sons Inc

Access to resources Recommend Favorite

The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 10, 2015-11 ,pp. : 1192-1199

John Wiley & Sons Inc

Access to resources Recommend Favorite

Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 1, 2018-01 ,pp. : 226-231

John Wiley & Sons Inc

Access to resources Recommend Favorite